trending Market Intelligence /marketintelligence/en/news-insights/trending/ERkPYmcav__tGHYbNHuGCg2 content esgSubNav
In This List

FSD Pharma to undertake 1-for-201 share consolidation, appoints director


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

FSD Pharma to undertake 1-for-201 share consolidation, appoints director

FSD Pharma Inc. is consolidating its class A multiple voting shares and its class B subordinate voting shares, each on a 1-to-201 basis.

Following consolidation, there will be 72 issued and outstanding class A shares, representing 276,660 votes or about 72% of FSD's voting rights.

Cobourg, Ontario-based FSD expects to commence trading the class B shares on the Canadian Securities Exchange on a post-consolidation basis under its existing name and ticker symbol starting Oct. 16, with a record date of Oct. 17.

The consolidation will reduce the number of FSD's issued and outstanding class B shares to about 7,874,809 from 1,582,966,252. This will allow the company to list class B shares on a major U.S. exchange.

Following the consolidation, the company will have about 1,033,782 stock options and warrants to purchase 576,499 class B shares outstanding.

Additionally, FSD said it appointed Stephen Buyer, a former U.S. representative from Indiana, to its board.